

IN THE CLAIMS:

Please add the following claims:

- 12. A combination suitable for treating a gastrin-dependent tumor, comprising:
- (i) an immunogen directed against growth of the tumor, and
 - (ii) one or more chemotherapeutic agents for treating the tumor.
- 13. The combination according to Claim 12, wherein the immunogen comprises an gastrin G17-peptide-containing immunogen.
- 14. The combination according to Claim 13, wherein the gastrin G17-peptide is conjugated to a diphtheria toxoid carrier.
- 15. The combination according to Claim 13, wherein the gastrin G17-peptide-containing immunogen comprises the gastrin G17 peptide, a protein carrier and a spacer peptide suitable for projecting the gastrin G17 peptide away from the protein carrier and for enhancing its capacity to bind lymphocyte receptors.
- 16. The combination according to Claim 13, wherein the gastrin G17-peptide is of SEQ ID NO.: 1.
- 17. The combination according to Claim 12 or 13, wherein the chemotherapeutic agents are selected from the group consisting of 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor and proglumide.
- 18. The combination according to Claim 12 or 13, further comprising a pharmaceutically acceptable carrier.
- 19. The combination according to Claim 12, for treating a gastrin-dependent tumor in a patient.